Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Medinet Co. Ltd. is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions, which are distributed across 2 distinct art units. This distribution indicates that the company's current legal efforts are split between different technical specialties at the USPTO. Managing these pending office actions in separate art units requires a strategy that can adapt to different examination standards.
The company's applications are being reviewed by 2 distinct examiners. The busiest examiner is SPENCER, ANDREA LYNNE MORRIS, who has a busiest examiner pending count of 1. This busiest examiner pending count of 1 shows how the workload is divided among the examiners involved in the company's prosecution. Each examiner is responsible for a portion of the total 2 pending office actions, requiring the company to maintain multiple lines of communication.
With multiple examiners and art units, the portfolio's current activity is not concentrated under a single official. Practitioners must tailor their responses to the specific feedback of SPENCER, ANDREA LYNNE MORRIS and the other assigned examiner. The Biotechnology & Pharmaceuticals focus remains the common thread across the pending office actions currently facing the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773241 | B-CELL ANTIBODY RECEPTOR AND USE THEREOF | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773241 | B-CELL ANTIBODY RECEPTOR AND USE THEREOF | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17773241 | B-CELL ANTIBODY RECEPTOR AND USE THEREOF | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103 | Final Rejection | — | Pending | Apr 29, 2022 |
| 16968146 | IMPROVED ALPHA-BETA T PROCESSED CELL PRODUCTION METHOD | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | — | Pending | Aug 06, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedinet Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrea Lynne Morris Spencer has the most, with 1 of Medinet Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
